CNQX

• Description:

  CNQX (FG9065) is a potent and competitive AMPA/kainate receptor antagonist with IC50s of 0.3 μM and 1.5 μM, respectively. CNQX is a competitive non-NMDA receptor antagonist[1]. CNQX blocks the expression of fear-potentiated startle in rats[5].

• Product Name Alternative:

  FG9065

• UNSPSC:

  12352005

• Hazard Statement:

  H410

• Target:

  IGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/CNQX.html

• Purity:

  99.65

• Solubility:

  DMSO : 20 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C1C(NC2=CC([N+]([O-])=O)=C(C#N)C=C2N1)=O

• Molecular Formula:

  C9H4N4O4

• Molecular Weight:

  232.15

• Precautions:

  H410

• References & Citations:

  [1]T Honoré, et al. Quinoxalinediones: Potent Competitive non-NMDA Glutamate Receptor Antagonists. Science. 1988 Aug 5;241 (4866) :701-3.|[2]Neuman RS, et al. Blockade of excitatory synaptic transmission by 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) in the hippocampus in vitro. Neurosci Lett. 1988 Sep 23;92 (1) :64-8.|[3]Alford S, et al. CNQX and DNQX block non-NMDA synaptic transmission but not NMDA-evoked locomotion in lamprey spinal cord. Brain Res. 1990 Jan 8;506 (2) :297-302.|[4]Pia Bäckström, et al. Attenuation of Cocaine-Seeking Behaviour by the AMPA/kainate Receptor Antagonist CNQX in Rats. Psychopharmacology (Berl) . 2003 Feb;166 (1) :69-76.|[5]Kim M, et al. Infusion of the non-NMDA receptor antagonist CNQX into the amygdala blocks the expression of fear-potentiated startle. Behav Neural Biol. 1993 Jan;59 (1) :5-8.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  AMPA Receptor; Kainate Receptor

• Citation 01:

  Acta Biomater. 2022 Oct 15:152:255-272.|Biomed Pharmacother. 2022 Jan:145:112446.|Cell Death Dis. 2022 Sep 12;13 (9) :786.|Cell Rep. 2025 May 14;44 (5) :115712.|Environ Sci Technol. 2023 Aug 22;57 (33) :12222-12233.|Front Cell Neurosci. 2019 Jun 25:13:276.|J Cell Mol Med. 2021 Aug;25 (15) :7342-7353.|J Integr Neurosci. 2022 Jun 28;21 (4) :121.|J Neurosci. 2024 Apr 10;44 (15) :e2062232024.|Nat Commun. 2024 May 15;15 (1) :4122.|Nat Neurosci. 2023 May;26 (5) :751-764.|PLoS Biol. 2025 Jan 27;23 (1) :e3003011.|SSRN. 2025 Jun 18.|Nat Commun. 2025 May 16;16 (1) :4560.

• CAS Number:

  [115066-14-3]